Company attributes
Other attributes
Synosia Therapeutics is a biotechnology company developing therapies for psychological and neurological illnesses that is headquartered in Basel, Switzerland and was founded in 2006.
On March 6, 2006 Synosia Therapeutics completed their series A funding round with $2.5 million in capital from undisclosed investors.
On January 5, 2007 Synosia Therapeutics completed a venture capital round with $32.5 million in funding from Versant Ventures, Novo Holdings, Abingworth, and 5AM Ventures.
On January 1, 2009 Synosia Therapeutics completed their series B funding round with $29 million in funding from Investor Growth Capital Limited (lead investor), Aravis Ventures (lead investor), Versant Ventures, Swiss Helvetia Fund, Novo Ventures, Abingworth, and 5AM Ventures.
On October 12, 2010 Synosia Therapeutics completed their series C funding round with $30 million in funding from UCB Pharma (lead investor), Versant Ventures, Swiss Halvetia Fund, Novo Holdings, Investor Growth Capital Limited, Aravis Ventures, and 5AM Ventures.
